Efficacy and safety of metreleptin therapy in patients with type 1 diabetes: A pilot study

Chandna Vasandani, Gregory O. Clark, Beverley Adams-Huet, Claudia Quittner, Abhimanyu Garg

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

OBJECTIVE: To study the efficacy and safety of metreleptin therapy in patients with suboptimally controlled type 1 diabetes mellitus (T1DM). RESEARCH DESIGN AND METHODS: After a baseline period of 4 weeks, five female and three male patients with T1DM (mean age 33 years, BMI 23.8 kg/m2) received metreleptin (0.08 mg/kg/day in females and 0.04 mg/kg/day in males) subcutaneously twice daily for 20 weeks followed by an off-therapy period of 4 weeks. RESULTS: Metreleptin therapy did not lower HbA1c significantly compared with the baseline value (mean difference20.19% [22.0 mmol/mol] and 20.04% [20.5 mmol/mol] at 12 and 20 weeks, respectively). Mean body weight reduced significantly by 2.6 and 4.7 kg (P = 0.003) and daily insulin dose by 12.6% and 15.0% at week 12 and 20 (P = 0.006), respectively. CONCLUSIONS: Metreleptin is safe but may not be efficacious in improving glycemic control in patients with T1DM, although it reduces body weight and daily insulin dose modestly.

Original languageEnglish (US)
Pages (from-to)694-697
Number of pages4
JournalDiabetes Care
Volume40
Issue number5
DOIs
StatePublished - May 1 2017

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Fingerprint Dive into the research topics of 'Efficacy and safety of metreleptin therapy in patients with type 1 diabetes: A pilot study'. Together they form a unique fingerprint.

  • Cite this